z-logo
Premium
Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development
Author(s) -
Friesen Phoebe,
Caplan Arthur L.,
Miller Jennifer E.
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13067
Subject(s) - formulary , pharmacy , context (archaeology) , conflict of interest , medicine , health care , family medicine , business , political science , finance , law , paleontology , biology
What is known and objective While many countries have central agencies responsible for formulary development, within the United States, each hospital, health care system, or insurance provider has their own pharmacy and therapeutic committee, leading to both inefficiencies and inequalities across formularies. The number and variety of processes within pharmacy and therapeutic committees also increases the likelihood that conflicts of interest will influence the development of formularies. We sought to determine how such influences could be reduced by reviewing international evidence related to the presence and harms of conflicts of interest in formulary development. Methods Several approaches have been taken to reduce the influence of conflicts of interest in pharmacy and therapeutics committee processes, including include disclosure, recusal, exclusion, universal consideration and dual committees. The feasibility of each of these approaches is considered in the context of the United States. Results and Discussion A proposal is drawn from the discussion of various approaches to conflicts of interest in pharmacy and therapeutics committees: multicenter formulary development. What is new and conclusion Multicentre formulary development, where resources are pooled across institutions, may lead to a reduction in the influence of conflicts of interest in pharmacy and therapeutics committee processes in the United States, increasing the chances of including the most safe, efficacious and cost‐effective drugs on formularies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here